New prostate surgery option available at WRH - CTV News

There’s a new, minimally invasive surgical option at Windsor Regional Hospital (WRH) to assist men experiencing symptoms of an enlarged prostate. The hospital has announced the introduction of the ThuLEP, thulium Laser Enucleation of the prostate. According to the hospital, it’s a significant advancement over traditional surgical approaches such as Transurethral Resection of the Prostate (TURP), green light laser, and open/simple prostatectomy. The new procedure is considered a state-of-the-art procedure and offers improved patient outcomes, reduced hospital stays, shorter catheterization times, and enhanced surgical efficiency. Dr. Haider Abed is a urologist at Windsor Regional Hospital. He did specialized training for one year and started the program with a colleague at Mackenzie Health in Richmond Hill. Dr. Abed says this is new technology for Windsor and Windsor is only third healthcare centre in Ontario to do the procedure.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.